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BACKGROUND AND PURPOSE: Intracranial stent placement assists in the coiling of wide-neck aneu-
rysms and aids in reconstructing and protecting the parent artery. In this study, we analyze our
experience in the use of the Neuroform system.
MATERIALS AND METHODS: Records of patients treated with a Neuroform stent from June 2003 to
September 2007 were retrieved from a data base for analysis of population characteristics, occurrence
of complications, and acute and midterm angiographic results.
RESULTS: Sixty-eight patients harboring 76 aneurysms located primarily in the anterior circulation were
treated. There were 5 cases (6.6%) of clot formation after deployment (1 with a permanent neurologic
deficit), 1 case of perioperative stent displacement with hemorrhage, and 5 cases (6.6%) of transient
neurologic deficit due to thromboembolic events. The morbidity-mortality rate at discharge was 2.9%.
One patient presented with a delayed in-stent thrombosis, and 3 others, with silent stenosis. Twenty-
four aneurysms (31.6%) were completely occluded in the initial embolization. However, a marked
increase in the occlusion rate was observed, with 44 of the 68 aneurysms (64.7%) examined at the
18-month follow-up and 26 of the 46 aneurysms (56.5%) examined in the 3-year follow-up presenting
with complete occlusion. At the end of the study, a neck remnant was present in 6 aneurysms (13%)
and a residual sac, in 7 (15.2%). Mean follow-up time was 25.7 months.
CONCLUSIONS: The present series demonstrates the relative safety and feasibility of the Neuroform
stentassisted coiling technique, which seems to provide better results over coiling alone for wide-
neck aneurysms. Angiographic results improve with time due to progressive thrombosis of the
aneurysm.
ABBREVIATIONS: ASA  aspirin; CI  confidence interval; D  largest aneurysm diameter; DSA 
digital subtraction angiography; GDC  Guglielmi detachable coil; ICA  internal carotid artery;
MCA  middle cerebral artery; MRA  MR angiography; OR  odds ratio; PICA  posterior inferior
cerebellar artery
The Neuroform stent system (Boston Scientific, Natick,Massachusetts) has been designed as an adjunctive tool in
the coiling of wide-neck aneurysms. It is a self-expandable
open-cell nitinol stent that can be used to bridge the aneurysm
neck and aids in reconstructing and protecting the parent ar-
tery by containing the coil mass inside the aneurysm sac. Nav-
igability was the main technical concern of the first-generation
Neuroform stent, while insufficient radial force and open cell
design have been subjects of discussion with the more recent
versions of Neuroform2 and Neuroform3.1
In the present series, we report and analyze our single-
center experience in the use of the Neuroform stent for treat-
ment of brain aneurysms. Feasibility, morbidity-mortality,
and acute and intermediate anatomic results are discussed in
light of recent medical literature. The main objectives of this
study were to evaluate the efficacy and safety of the Neuroform
stent in treating unruptured aneurysms unsuitable for stand-




Medical records of all patients treated for brain aneurysms from June
2003 to September 2007 were retrospectively retrieved from a pro-
spectively maintained computerized data base in the Interventional
Neuroradiology Department of our institution. An institutional re-
view board approval was obtained for this retrospective study.
Neuroform stentassisted coiling was attempted in 82 aneurysms
(74 patients), but 6 were not stented (6/82, 7.3%) due to technical
difficulties such as poor navigability of the Neuroform2 device (2
cases) or inability to reach the target artery.
Therefore, 68 patients harboring 76 cerebral aneurysms were
treated by using Neuroform stents. A retrospective review of medical
files allowed retrieval of the following population characteristics: age
at treatment; sex; number of aneurysms; number of endovascular
procedures performed; location of aneurysms; length of follow-up;
availability of pre- and postprocedural radiologic images; occurrence
of any perioperative, postoperative, or delayed complications; and the
situation in which a stent-based technique was chosen as a first-line
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treatment for wide-neck aneurysms or as a retreatment option for a
recanalization.
No aneurysm was stented in the acute phase of a subarachnoid
hemorrhage. In cases of retreatment of a previously ruptured aneu-
rysm, the second endovascular procedure was performed at least 30
days after the bleeding episode.
Evaluation of the Aneurysm Neck
Neuroform stents were used in 2 different situations: wide-neck an-
eurysm (dome-to-neck ratio 2 or neck diameter 4 mm) and un-
favorable anatomy, such as MCA trifurcation or aneurysm-neck-to-
parent-artery diameter ratio 1.
Endovascular Procedures
Every procedure was performed via a femoral approach with the pa-
tient under general anesthesia. A 6F guiding catheter was introduced
through a femoral sheath into the carotid or vertebral artery. The
radiologic examination of the target vessel was performed by using a
biplane angiographic system (Neurostar T.O.P.; Siemens, Erlangen,
Germany) and 3D rotational angiography.
Between 2003 and 2007, 3 successive generations of the Neuro-
form stent system were developed by the manufacturer and used in
our department. The appropriate Neuroform stent size and length
were chosen according to the largest diameter of the parent artery and
the length of the aneurysm neck. The goal was to ensure arterial wall
coverage of at least 5 mm beyond both the distal and proximal limits
of the neck. Microcatheters were positioned either through the stent
interstices or positioned inside the aneurysmal sac before stent de-
ployment (“jailing” technique).
Anticoagulation/Antiplatelet Regimen
Patients were prepared with a loading dose of clopidogrel (300 mg)
the day before the endovascular treatment. During the procedure,
they were anticoagulated with a bolus of standard heparin (70 –100
IU/kg) followed by an intravenous drip through an automated sy-
ringe (40 – 60 IU/kg/h) to maintain an activated clotting time of 250
seconds. At the end of the procedure, they received an IV dose of
250 –500 mg of ASA. Then, a daily dose of clopidogrel (75 mg) and
ASA (75 mg) was administered for 2 or 3 months. Since September
2006, platelet inhibition has been tested by using a point of care (Veri-
fyNow P2Y12 Test; Accumetrics, San Diego, California) system im-
mediately before starting the procedure. If the patient was considered
a nonresponder (40% platelet inhibition), a reloading dose of clo-
pidogrel (300 mg) was administered as soon as the patient awakened
from anesthesia.
Anatomic Result Assessment
Each angiographic result was categorized according to the revised
Raymond classification into 1 of the following groups: complete oc-
clusion, remnant neck, and residual aneurysm.
Follow-Up
Follow-up examinations with MRA were scheduled at 6 and 18
months with DSA and at 3 years with MRA. In cases of early recana-
lization, the DSA control was scheduled earlier to assess the need for
retreatment.
Statistical Analysis
Frequencies and percentages were calculated for categoric variables,
and means and SDs, for continuous variables. Patients treated for 2
aneurysms were analyzed and categorized independently. Compari-
sons of rates of complete aneurysm occlusion between the immediate
postoperative and follow-up terms and between follow-up terms were
performed by using the 2 test. To verify possible associations be-
tween treatment efficacy and the type of coil used, we compared the
rates of complete occlusion in each group of coil type (bare coil,
bioactive coil, or HydroCoil [MicroVention Terumo, Aliso Viejo,
California], 50% of the total length) at every follow-up. This com-
parison was performed by using the 2 or the Fisher exact test when
samples were insufficient (5). To avoid confounding factors, we
constructed a model of logistic regression for each follow-up term.
Possible confounding factors considered were sex, initial aneurysm
diameter, and type of procedure (a first choice for a wide-neck aneu-
rysm or a retreatment option for a recanalized aneurysm). Those
results were analyzed by using ORs and 95% CIs. The association
between 2 compared variables was considered significant if the 95%
CI of the OR did not include 1. The level of statistical significance used
was P  .05 for the whole study. Statistical analysis was performed by
using the SAS 9.1 software (SAS Institute, Cary, North Carolina).
Results
Patient Population
Sixty-eight patients harboring 76 cerebral aneurysms were
treated with a Neuroform stentassisted technique between
June 2003 and September 2007, 48 women and 20 men. The
mean age at the time of the endovascular treatment was 53.2 
15.2 years. The Neuroform stent was used as a first option in
51 procedures (67.1%) and for treating a partial aneurysm
recanalization in 25 others. Two retreatment procedures were
performed for aneurysms that had regrowth after surgical
intervention.
The mean follow-up period was 25.7  14 months. At the
time of this study, 68 of the 76 aneurysms had been followed
for more than 1 year.
Implanted Neuroform Stents
A single first-generation Neuroform stent was implanted
once. The Neuroform2 stent was implanted for treatment of
26 aneurysms in 24 patients, and the Neuroform3 stent was
used for treatment of 49 aneurysms in 45 patients. Most aneu-
rysms were treated by using a single-stent deployment (n 
70).
Two kissing stents in the same procedure were used for
treating an aneurysm of the top of the basilar artery. There
were 2 cases of telescopic stent deployment. A rescue stent or a
finishing stent deployment following the balloon remodeling
technique was performed in a limited number of cases (n  8).
Aneurysm Location
Most aneurysms (89.5%) were located in the anterior circula-
tion. Patients with carotid-ophthalmic aneurysms represented
one-third of the population, and the MCA was the second
most frequent location. Aneurysm locations are summarized
in Table 1.
Aneurysm Size
The mean size of the 76 treated aneurysms was 8.2  5.3 mm.
They were categorized into 4 different groups: small (6 mm,
25 cases, 32.9%), medium (6 –10 mm, 31 cases, 40.8%), large
132 Maldonado  AJNR 32  Jan 2011  www.ajnr.org
(10 –25 mm, 19 cases, 25%), and giant (25 mm, 1 case,
1.3%).
Types of Coils
Different types of coils were used for stent-assisted emboliza-
tion. Bare platinum coils (GDC from Boston Scientific; Trufill
from Cordis, Miami Lakes, Florida; and MicroPlex from
MicroVention were used in 11 cases (14.4%). Bioactive coils
(Matrix from Boston Scientific and Nexus from ev3, Irvine,
California) were used in 41 (53.9%), and HydroCoils (Micro-
Vention) were used in 24 cases (31.5%). Generally, bare coils
or bioactive coils were used to treat small or medium-sized
aneurysms (44 of 56, 78.6%). HydroCoils were preferred for
large or giant aneurysms (12 of 20, 60%). The main criterion
for choosing coil type was aneurysm size.
Procedure-Related Complications
There was 1 case of secondary stent displacement, probably
due to impingement of the microguidewire through the open
cells at the time of retrieval. The initial deployment was accu-
rate. The patient had subarachnoid bleeding and worsening of
a pre-existing neurologic deficit (final modified Rankin Scale
score  4).
There were 5 cases of clot formation near the neck of the
aneurysm after stent deployment (during aneurysm coiling).
Those patients received a glycoprotein IIb/IIIa inhibitor dose
with good angiographic results, but 1 patient had a mild per-
manent deficit (modified Rankin Scale score  2).
In the immediate postprocedural period, 5 patients pre-
sented with acute neurologic deficits due to downstream
thromboembolic events, confirmed by MR imaging. Those
patients received an IV bolus of abciximab (25 mg/kg), then a
12-hour infusion (125 g/kg). A complete recovery was ob-
tained in all cases. At discharge, there was no mortality, and
the prevalence of a persistent neurologic deficit was 2.9%
(2/68 patients).
Delayed Complications
A 5-month delayed ischemic stroke due to intrastent throm-
bosis was observed. The patient had been treated for an ante-
rior cerebral artery aneurysm and was still under ASA therapy.
Two years after the stroke, his modified Rankin Scale score was
3.
Three cases of mild clinically silent in-stent stenosis were
observed. In 2 of them, a paraclinoid ICA and an MCA aneu-
rysm, the stenosis was depicted on the 6-month MRA. In the
third, an ICA bifurcation aneurysm, it was characterized by
DSA 15 months after the embolization.
Immediate and Midterm Results
A follow-up angiogram (MRA or DSA) was available for all
aneurysms treated. At the time of this study, the overall time of
follow-up ranged from 4 to 52 months (mean, 25.7  14.0
months,). Sixty-six of the 76 aneurysms had a follow-up pe-
riod longer than 1 year. Three patients were no longer fol-
lowed after 4, 6, and 9 months because of transfer for fol-
low-up elsewhere. Three others died between 6 and 8 months
after treatment for reasons independent of their brain
aneurysms.
Angiographic results are presented for the immediate post-
operative and 3 follow-up terms, at approximately 6 months,
1 year and 6 months, and 3 years (Table 2). The mean fol-
low-up periods at the moment of each analysis were 6.54 
1.56 months, 16.41  3.83 months, and 37.09  9.6 months,
respectively.
On the immediate postprocedural angiogram, 24 of the 76
treated aneurysms (31.6%) were completely occluded. Twenty
aneurysms (26.3%) presented with a neck remnant and 32
(42.1%) showed a residual filling inside the aneurysm sac.
At the time of this study, 58 aneurysms had already been
re-examined at the first follow-up, 68 at the second, and 46 at
the third. On the first control angiogram, 37 (63.8%) pre-
sented with a complete occlusion, which was a statistically sig-
nificant improvement over the immediate postoperative re-
sults. Seven aneurysms (12.1%) presented with a neck
remnant, and 14 (24.1%), with a residual aneurysm.
The rates of complete occlusion at each of the 3 follow-up
terms were statistically different from the results observed on
the immediate postoperative angiogram: 63.8% (n  37, P 
.01) for the first, 64.7% (n  44, P  .01) for the second, and
56.5% (n  26, P  .01) for the third. The percentage of
complete occlusion was relatively stable after the first follow-
up. No statistical difference was found when comparing the
first with the second follow-up (P  .91), the first with the
third follow-up (P  .45), or the second with the third fol-
low-up (P  .37).
Progressive thrombosis and subsequent increase of the de-
gree of aneurysm occlusion between the immediate postoper-
ative and follow-up angiograms were observed in 50% of the
treated aneurysms (38/76). Of the initial population of 76 an-
eurysms, 13 (17.1%) that presented with a neck remnant after
stent-assisted coiling were completely occluded at the first fol-
low-up. Twenty-two (28.9%) presenting with a residual sac on
the immediate postoperative angiogram progressed to com-
plete occlusion, and 3 others (3.9%), to a neck remnant. The
conditions of 17 patients with complete occlusion remained
stable (17/76; 22.4%). However, 6 aneurysms with an initial
complete occlusion and 5 with a neck remnant recanalized.
The analysis by aneurysm size subgroups shows similar
rates of complete occlusion for small, middle-sized, and large
aneurysms (Table 3). Six cases (8.8%) of major recurrence
Table 1: Distribution of 76 aneurysms treated with Neuroform stent









Anterior circulation 46 (60.5%) 22 (28.9%) 68 (89.5%)
Carotid-ophthalmic 20 5 25
MCA 13 6 19
Intracavernous carotid 5 0 5
Pericallosal artery 0 1 1
ICA bifurcation 4 3 7
Supraclinoidal ICA 1 4 5
Anterior communicating 3 3 6
Posterior circulation 5 (6.6%) 3 (3.9%) 8 (10.5%)
Top basilar artery 2 2 4
Basilar artery 1 0 1
PICA 1 1 2
Posterior cerebral artery 1 0 1
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were detected and were treated after the first follow-up, and 1
case, after the second.
Rates of complete occlusion were also analyzed by coil type.
The highest rate of complete occlusion at the final follow-up
was obtained in the group treated with HydroCoils (60%). For
the largest group, those treated with bioactive coils, the com-
plete occlusion rate was 55.2%. A rate of 57.1% of completely
treated aneurysms was obtained with bare coils. No statisti-
cally significant association was encountered between com-
plete occlusion and coil type at any time during of the fol-
low-up period.
Discussion
The debate on the ideal management of unruptured intracra-
nial aneurysms is far from finished. The outcome of coil em-
bolization is related, in part, to aneurysm geometry. Aneu-
rysms with wide necks are often poor candidates for treatment
with coiling alone. A wide-neck configuration prevents com-
plete packing, resulting in higher rates of regrowth, often re-
quiring subsequent retreatment. In addition, implanted coils
may herniate from the aneurysm sac into the parent artery,
causing thromboembolic complications or vessel occlusion.
The balloon-assisted or “remodeling” technique presents
total occlusion rates ranging from 67% to 100% in aneurysms
that are considered difficult to treat.2-4 This technique poten-
tially increases the risk of ischemia from thromboembolic
events related to the temporary occlusion of the parent artery,
repeated inflations, and the use of 2 microcatheters. Other
risks are vasospasm, occlusion of perforators, vessel damage,
and aneurysm regrowth or bleeding from the repetitive stress
transmitted by the balloon.3,5,6 The increase in the incidence
of thromboembolic complications with balloon-assisted coil-
ing is not invariably encountered. However, the presence of
wide-neck aneurysms has been independently associated with
thrombus formation (whereas the use of clopidogrel has been
considered to be protective).7
Since the advent of self-expandable flexible stents, stent-
assisted coiling has become a viable option in the treatment of
wide-neck aneurysms and, more recently, for medium and
small-sized aneurysms.8 Stents prevent herniation of coils into
the parent artery, alter flow dynamics, increase packing atten-
uation, favor thrombosis, and may provide a scaffold for en-
dothelial growth.9,10
From the beginning of the present series until January
2007, Neuroform stents were used for treating cerebral aneu-
rysms in our department. More recently, Enterprise stents
(Cordis) have also been available. Frequent reasons for prefer-
ring a Neuroform stent were situations in which an open cell
device was needed, as in the case of crossing the stent with a
microcatheter. Furthermore, with a Neuroform stent, it seems
easier to access the aneurysm sac in cases of microcatheter
kickback into the parent vessel.
Poor immediate angiographic results can occur due to the
inherent difficulty of crossing the stent struts in the first in-
stance or in regaining access into the aneurysm. Denser pack-
ing seems more likely when a finishing stent follows a 3D coil
framing or a protective balloon remodeling technique. The
reported acute angiographic results are extremely variable,
with rates of complete occlusion of 17%,11 26.3%,12,13 32%
(our own series), 35%,14 45.9%,15,16 and 94.4%.17
Technical failures that occurred with the first- and second-
generation Neuroform stents were mainly related to poor nav-
igability through tortuous vessels.1 An inappropriate opening
could result in unsatisfactory deployment with only partial
covering of the aneurysm neck, which could be overcome by
placement of a second stent.18
High procedural adverse event rates (21.4%) and adverse
outcomes have been reported in the acute phase of ruptured
aneurysms treated with stent assistance.19,20 However, proce-
dural complications were not increased by the use of the Neu-
roform stent in incidental aneurysms. Iatrogenic hemorrhages
occur rarely but may be life-threatening. Rebleeding from a
previously ruptured aneurysm, vessel perforation by the mi-
croguidewire, and delayed intracranial hematoma or groin he-
matoma account for significant morbidity and mortality.11,21
To our knowledge, subarachnoid bleeding resulting from a




(6.54  1.56 mo)
Second Follow-Up
(16.41  3.83 mo)
Third Follow-Up
(37.09  9.6 mo)
Complete occlusiona 24 (31.6%) 37 (63.8%) 44 (64.7%) 26 (56.5%)
Neck remnant 20 (26.3%) 7 (12.1%) 9 (13.2%) 6 (13.0%)
Residual aneurysm 32 (42.1%) 14 (24.1%) 9 (13.2%) 7 (15.2%)
Recanalization 0 0 6 (8.8%) 7 (15.2%)
Total 76 58 68 46
a The rates of complete occlusion on the immediate postoperative angiograms are statistically different from the results observed at the first (P  .01), second (P  .01), and third (P 
.01) follow-up terms. The percentage of complete occlusion is relatively stable after the first follow-up examination, without statistical differences between the first and second follow-up
terms (P  .91), the first and third follow-up terms (P  .45), or the second and third follow-up terms (P  .37).
Table 3: Evolution of 76 cerebral aneurysms treated with Neuroform stent systemassisted coiling by aneurysm size
No. of
Aneurysms




(6.54  1.56 mo)a
Second Follow-Up
(16.41  3.83 mo)a
Third Follow-Up
(37.09  9.6 mo)a
D  6 mm 23 10 (43.5%) 11 (78.6%) 14 (70%) 9 (69.2%)
6  D  10 mm 32 9 (28.1%) 16 (66.7%) 19 (79.2%) 9 (64.3%)
10  D  25 mm 20 5 (25%) 9 (47.4%) 11 (64.7%) 8 (66.7%)
25 mm 1 0 1 (100%) 0 –b
a Mean  SD.
b Not yet performed at the time of this study.
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Neuroform stent displacement while retrieving the microgu-
idewire has not been reported until now. We presume that the
case we describe here resulted from guidewire encroachment
through the stent cells.
In our experience, the combination of a loading dose of
clopidogrel the day before the procedure, a real-time platelet
inhibition test in the interventional operating room, and a
double regimen of antiaggregation after the endovascular
treatment allowed the reduction of the incidence of thrombo-
embolic events by 2-fold, by using as a baseline a previously
reported series of the same group.22 The largest series to date
(142 aneurysms) reports 2.8% permanent morbidity and 2%
mortality associated with use of the Enterprise stent.21 Fiorella
et al15 reported a higher rate of thromboembolic events (9.3%)
by using the Neuroform stent. However, some patients were
treated in the acute setting of subarachnoid hemorrhage.
Other authors declared very low rates (4%)23 or no adverse
events at all.12
Antiplatelet agents are used in patients intended for endo-
vascular stent placement. Muller-Schunk et al24 reported that
a significant number (28%) of individuals were nonre-
sponders to clopidogrel. In their series, the response was eval-
uated by impedance aggregometry by using a point-of-care
assay. All thromboembolic events (10%) registered were in the
group of nonresponders. Furthermore, insufficient platelet in-
hibition has been associated with an increased risk of throm-
bus formation within the stented segment.11 Thus, a level of
40% of platelet inhibition by using the VerifyNow system has
been recommended.25,26
Delayed in-stent thrombosis has been related to platelet
medication discontinuation or clopidogrel resistance. Sub-
acute stent thrombosis can occur even in patients who are
treated with standardized antiplatelet therapy. In a recent se-
ries, 3 patients harboring aneurysms of the basilar artery, pos-
terior inferior cerebellar artery, and anterior cerebral artery
were treated with placement of a Neuroform stent and pre-
sented with subacute symptomatic in-stent thrombosis (at
days 1, 2, and 12, respectively). In 2 cases, they were treated
successfully with superselective local infusion of recombinant
tissue plasminogen activator.27
We observed 1 case of delayed in-stent thrombosis and 3
cases of silent mild in-stent stenosis during the follow-up pe-
riod. Stable in location and extent, conditions in those 3 pa-
tients did not require any specific treatment. The high sensi-
tivity of 3D time-of flight MR angiography for residual flow in
treated cerebral wide-neck aneurysms has been recog-
nized.28,29 However, stent-related artifacts compromise the
evaluation of the true lumen of the parent artery.30 Fiorella et
al31 reported an incidence of 5.8% of delayed Neuroform in-
stent stenosis. In their series of 156 aneurysms, 9 patients de-
veloped a moderate-to-severe stenosis and 2 of them had a
complete vessel occlusion. Two patients developed focal neu-
rologic signs in the first 3 months that followed the stent im-
plantation and were treated with balloon angioplasty. One pa-
tient required a subsequent superficial temporal-artery-to-
MCA bypass. On the other hand, spontaneous resolution was
documented in 4 of 7 asymptomatic cases, while 2 progressed
to complete occlusion.
Achieving complete and stable occlusion is still a challenge.
Recanalization rates remain suboptimal, which has been a par-
ticular problem in subjects with large or wide-neck aneurysms
or aneurysms in certain locations such as the carotid-ophthal-
mic artery or MCA.32 In the series of Raymond et al,33 (n 
501) of ruptured and unruptured aneurysms, important pre-
dictors of angiographic recurrence were aneurysm size (10
mm), treatment during the acute phase of rupture, incomplete
initial occlusion, and duration of follow-up. In another study
by Murayama et al,34 an analysis of an 11-year experience with
embolization of cerebral aneurysms with GDC coils showed
an overall recanalization rate of 20.9%, which was correlated
to the size of the dome and of the neck of the aneurysm. Ad-
ditional thrombosis was observed in 41.4% of small aneu-
rysms with small necks, while it occurred in only 17.6% of
small aneurysms with wide necks.
Techniques implemented to minimize recanalization in-
clude complex-shaped coil packing,35 use of bioactive coils,
use of HydroCoils, and the use of adjunctive devices.36,37 Clin-
ical results with coils coated with the biocompatible copoly-
mer polyglycolic/polylactic acid38,39 (Matrix and Nexus coils)
failed to prove beneficial in preventing recanalization, even
though the occurrence of progressive thrombosis was docu-
mented.38 The overall recurrence for small and large aneu-
rysms treated with HydroCoils does not seem lower than the
previously published rates with platinum coils, as character-
ized by the initial angiographic results of the HydroCoil for
Endovascular Aneurysm Occlusion study.40
Stents may contribute to the progression of thrombosis,
independent of the size of the aneurysm and the type of coils
used. Fiorella et al15 reported, in patients treated with Neuro-
form stentassisted coiling, an improvement of anatomic re-
sults with progressive thrombosis in 52% of the cases. In the
same series, the results were stable in 25% of cases and recan-
alization occurred in 23%. Lubicz et al,12 by using Leo (Balt,
Montmorency, France) and Enterprise stents, observed fur-
ther thrombosis in 53% of aneurysms coiled with MicroPlex
bare coils or GDCs. The final results of the present series are
similar to those previously reported, with progressive throm-
bosis of the aneurysm documented in 55%, unchanged results
in 27.7%, and recanalization in 17.5% of cases.
The overall complete occlusion rate obtained with stent-
assisted coiling seems superior to results obtained with coils
alone34 or other adjunctive devices32 in cases of large or com-
plex aneurysms. Sedat et al23 documented, at a mean fol-
low-up of 42 months, 9.5% of aneurysmal regrowth. In our
series, a relatively small number of major recurrences requir-
ing retreatment are reported, with a complete occlusion rate of
50%.
Our study had limitations, including long-term results still
not being available and a retrospective single-center design.
Future perspectives should include the analysis of late angio-
graphic and clinical outcomes. This would help intervention-
ists in identifying the best candidates for stent placement and
in taking into consideration accurate prognostic factors,
which may go beyond aneurysm morphology.
Conclusions
The present series demonstrates that stent-assisted coiling
techniques for treatment of difficult cerebral aneurysms can
be feasible, effective, and relatively safe with the Neuroform
stent system. This approach presents a small-to-moderate risk
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of periprocedural complications or early recurrence. Never-
theless, the angiographic results presented here indicate that
complete occlusion rates improve with time, due to progres-
sive thrombosis of the aneurysm sac.
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